245 related articles for article (PubMed ID: 23735593)
21. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies.
Kibret KT; Moges Y; Memiah P; Biadgilign S
Infect Dis Poverty; 2017 Jan; 6(1):7. PubMed ID: 28093078
[TBL] [Abstract][Full Text] [Related]
22. Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens.
Zhu Y; Zhu L; Davies Forsman L; Paues J; Werngren J; Niward K; Schön T; Bruchfeld J; Xiong H; Alffenaar JW; Hu Y
Antimicrob Agents Chemother; 2023 May; 67(5):e0170022. PubMed ID: 37097151
[TBL] [Abstract][Full Text] [Related]
23. Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis.
van der Laan LE; Garcia-Prats AJ; McIlleron H; Abdelwahab MT; Winckler JL; Draper HR; Wiesner L; Schaaf HS; Hesseling AC; Denti P
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0061123. PubMed ID: 37971239
[TBL] [Abstract][Full Text] [Related]
24. Cycloserine Induced Suicidal Tendencies and Kanamycin Induced Ototoxicity in Indian MDR-TB Patient: A Case Report.
Jangra MS; Chhabra M
Curr Drug Saf; 2018; 13(3):211-213. PubMed ID: 29866015
[TBL] [Abstract][Full Text] [Related]
25. Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis.
Prasad R; Singh A; Srivastava R; Hosmane GB; Kushwaha RA; Jain A
Indian J Tuberc; 2016 Apr; 63(2):106-14. PubMed ID: 27451820
[TBL] [Abstract][Full Text] [Related]
26. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.
Sotgiu G; Centis R; D'Ambrosio L; Alffenaar JW; Anger HA; Caminero JA; Castiglia P; De Lorenzo S; Ferrara G; Koh WJ; Schecter GF; Shim TS; Singla R; Skrahina A; Spanevello A; Udwadia ZF; Villar M; Zampogna E; Zellweger JP; Zumla A; Migliori GB
Eur Respir J; 2012 Dec; 40(6):1430-42. PubMed ID: 22496332
[TBL] [Abstract][Full Text] [Related]
27. High Incidence of Psychiatric Disorders Associated with Cycloserine Treatment of Multidrug-Resistant Tuberculosis Patients: A Cohort Study in Beijing, China.
Pang Y; Liu R; Song Y; Lv Z; Gao M; Nie L; Ge Q; Wu X
Infect Drug Resist; 2022; 15():3725-3732. PubMed ID: 35859910
[TBL] [Abstract][Full Text] [Related]
28. Making optimal use of available anti-tuberculosis drugs: first steps to investigate terizidone.
Alffenaar JWC; Peloquin CA; Migliori GB
Int J Tuberc Lung Dis; 2018 Jan; 22(1):2. PubMed ID: 29297417
[No Abstract] [Full Text] [Related]
29. Linezolid in the treatment of multidrug-resistant tuberculosis.
Schecter GF; Scott C; True L; Raftery A; Flood J; Mase S
Clin Infect Dis; 2010 Jan; 50(1):49-55. PubMed ID: 19947856
[TBL] [Abstract][Full Text] [Related]
30. Cycloserine induced psychosis with hepatic dysfunction.
Tandon VR; Rani N; Roshi ; Gupta R; Arora M; Khajuria V; Mahajan V
Indian J Pharmacol; 2015; 47(2):230-1. PubMed ID: 25878391
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases.
von der Lippe B; Sandven P; Brubakk O
J Infect; 2006 Feb; 52(2):92-6. PubMed ID: 15907341
[TBL] [Abstract][Full Text] [Related]
32. Programmes and principles in treatment of multidrug-resistant tuberculosis.
Mukherjee JS; Rich ML; Socci AR; Joseph JK; Virú FA; Shin SS; Furin JJ; Becerra MC; Barry DJ; Kim JY; Bayona J; Farmer P; Smith Fawzi MC; Seung KJ
Lancet; 2004 Feb; 363(9407):474-81. PubMed ID: 14962530
[TBL] [Abstract][Full Text] [Related]
33. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.
Anger HA; Dworkin F; Sharma S; Munsiff SS; Nilsen DM; Ahuja SD
J Antimicrob Chemother; 2010 Apr; 65(4):775-83. PubMed ID: 20150181
[TBL] [Abstract][Full Text] [Related]
34. Risk Factors for Multidrug-resistant Tuberculosis.
Rumende CM
Acta Med Indones; 2018 Jan; 50(1):1-2. PubMed ID: 29686169
[TBL] [Abstract][Full Text] [Related]
35. New treatment options for multidrug-resistant tuberculosis.
Field SK; Fisher D; Jarand JM; Cowie RL
Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
[TBL] [Abstract][Full Text] [Related]
36. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
Laurence YV; Griffiths UK; Vassall A
Pharmacoeconomics; 2015 Sep; 33(9):939-55. PubMed ID: 25939501
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.
Prasad R; Verma SK; Sahai S; Kumar S; Jain A
Indian J Chest Dis Allied Sci; 2006; 48(3):183-6. PubMed ID: 18610675
[TBL] [Abstract][Full Text] [Related]
38. Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran.
Mirsaeidi SM; Tabarsi P; Khoshnood K; Pooramiri MV; Rowhani-Rahbar A; Mansoori SD; Masjedi H; Zahirifard S; Mohammadi F; Farnia P; Masjedi MR; Velayati AA
Int J Infect Dis; 2005 Nov; 9(6):317-22. PubMed ID: 16183321
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis.
Chang MJ; Jin B; Chae JW; Yun HY; Kim ES; Lee YJ; Cho YJ; Yoon HI; Lee CT; Park KU; Song J; Lee JH; Park JS
Int J Antimicrob Agents; 2017 Jun; 49(6):677-687. PubMed ID: 28408267
[TBL] [Abstract][Full Text] [Related]
40. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
